A citation-based method for searching scientific literature

Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Byoung Chul Cho, Myung-Ju Ahn. J Thorac Oncol 2018
Times Cited: 54



Solange Peters, D Ross Camidge, Alice T Shaw, Shirish Gadgeel, Jin S Ahn, Dong-Wan Kim, Sai-Hong I Ou, Maurice Pérol, Rafal Dziadziuszko, Rafael Rosell, Ali Zeaiter, Emmanuel Mitry, Sophie Golding, Bogdana Balas, Johannes Noe, Peter N Morcos, Tony Mok. N Engl J Med 2017
Times Cited: 1263




List of shared articles



Times cited

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
14

Methods for actionable gene fusion detection in lung cancer: now and in the future.
Pasquale Pisapia, Francesco Pepe, Roberta Sgariglia, Mariantonia Nacchio, Gianluca Russo, Gianluca Gragnano, Floriana Conticelli, Maria Salatiello, Caterina De Luca, Ilaria Girolami,[...]. Pharmacogenomics 2021
1


Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
3

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
56

Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review.
Gianmarco Leone, Francesco Passiglia, Paolo Bironzo, Valentina Bertaglia, Silvia Novello. Transl Lung Cancer Res 2020
0

The role of plasma genotyping in ALK- and ROS1-rearranged lung cancer.
Ibiayi Dagogo-Jack, Lauren L Ritterhouse. Transl Lung Cancer Res 2020
4

Treatment of oncogene-driven non-small cell lung cancer.
Elisabeth A Kastelijn, Adrianus J de Langen, Bas J M Peters. Curr Opin Pulm Med 2019
6

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
5

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee,[...]. Clin Cancer Res 2020
34

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
4

A Radiologist's Guide to the Changing Treatment Paradigm of Advanced Non-Small Cell Lung Cancer: The ASCO 2018 Molecular Testing Guidelines and Targeted Therapies.
Lydia Chen, Daniel A Smith, Bhanusupriya Somarouthu, Amit Gupta, Kianoush Ansari Gilani, Nikhil H Ramaiya. AJR Am J Roentgenol 2019
2

Evaluating entrectinib as a treatment option for non-small cell lung cancer.
Jiyun Lee, Sehhoon Park, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Expert Opin Pharmacother 2020
6

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Patrick R Halliday, Collin M Blakely, Trever G Bivona. Curr Oncol Rep 2019
53